
Kyowa Kirin’s istradefylline (Nourianz) is now available in the United States as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) that are experiencing “off” episodes.

Kyowa Kirin’s istradefylline (Nourianz) is now available in the United States as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson’s disease (PD) that are experiencing “off” episodes.

The International Society of Oncology Pharmacy Practitioners global position on oncology biosimilar use covers regulation and evaluation, implementation, education, and monitoring.

Top news of the day from across the health care landscape.

Expanded access to direct-acting antiviral drugs are vital to achieve elimination targets set by the World Health Organization for hepatitis C virus infections.

The Pharmacy Technician Certification Board (PTCB) has launched 2 specialty areas of Assessment-Based Certificate Programs: Technician Product Verification (TPV) and Medication History.

Top news of the day from across the health care landscape.

In the wake of California’s drug transparency law, an analysis by state health officials on pricing trends found that drug companies raised the whole acquisition cost dramatically for many drugs.

A report by the Institute for Clinical and Economic Review lists the top drugs with the greatest price increases not supported by new clinical evidence.

New study provides evidence that the use of antiretroviral therapy alters the formation or stabilization of HIV latent reservoirs.

Top news of the day from across the health care landscape.

Lasmiditan (Reyvow, Eli Lilly) resolved pain and most bothersome symptoms within 2 hours of treatment in patients with migraine.

Top news of the week from Specialty Pharmacy Times.

This article is the third in a series on difficult to pronounce drug names.

Top news of the day from across the health care landscape.

A phase 3 study assessed the efficacy and safety of plitidepsin (Aplidin) in combination with dexamethasone in patients with relapsed/refractory multiple myeloma.

Top news of the day from across the health care landscape.

Long-term treatment with dupilumab showed benefit in adolescents with atopic dermatitis comparable with the treatment’s effect in adults.

The grants were awarded through the Orphan Products Clinical Trials Grants Program, which is funded by Congress.

Researchers find 4 genetic variants that are strongly associated with the risk of acute lymphoblastic leukemia in children with Down syndrome.

Prescription medications and other health care items, including vitamins and supplements, eyewear, and natural medicine, such as pharmaceutical-grade CBD oil, is being delivered in the Dallas-Fort Worth (DFW) area with service to homes and offices.

Ramucirumab (Cyramza) in combination with erlotinib delayed disease progression in previously untreated patients with EGFR-mutated non-small cell lung cancer.

A webinar held by Trellis Rx discussed actionable ways to establish a successful clinic-based specialty pharmacy approach.

Top news of the day from across the health care landscape.

Erythropoietic protoporphyria is a rare metabolic disorder where exposure to light may be extremely painful for affected individuals.

Wilate, a von Willebrand factor replacement therapy, was approved for use in patients with hemophilia A for routine prophylaxis and on demand treatment and control of bleeding episodes.

Certain cancer agents may have drug-food or drug-drug interactions that alter exposure to the medication, resulting in a need for individualized dosing.

The National Association of Specialty Pharmacy's annual meeting is one of the industry’s only conferences where all stakeholders can fully participate.

Top news of the day from across the health care landscape.

Study finds health-related quality of life is often not collected for novel cancer drugs when they are submitted for reimbursement.

The new drug application for PF708 was submitted under the 505(b)(2) regulatory pathway with teriparatide injection as the reference drug.